Michael L.  Levitz net worth and biography

Michael Levitz Biography and Net Worth

On August 10, 2020, Michael Levitz was appointed Executive Vice President, Chief Financial Officer and Treasurer. Prior to joining Anika, Mr. Levitz served as Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a global innovative medical device and drug delivery company. From 2009 to 2015, he was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), Mr. Levitz served in various capacities including Vice President and Corporate Controller. He began his career in the high technology audit practice at Arthur Andersen LLP. In 2011, he was a finalist for the Boston Business Journal’s Chief Financial Officer of the Year award.

Mr. Levitz earned his Bachelor of Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant.

How old is Michael L. Levitz?

Mr. Levitz is currently 50 years old. There are 4 older executives and no younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics is Mr. Mark Namaroff, Executive Director of Investor Relations & Corporate Communications, who is 61 years old. Learn More on Michael L. Levitz's age.

How do I contact Michael L. Levitz?

The corporate mailing address for Mr. Levitz and other Anika Therapeutics executives is 32 WIGGINS AVENUE, BEDFORD MA, 01730. Anika Therapeutics can also be reached via phone at (781) 457-9000 and via email at [email protected]. Learn More on Michael L. Levitz's contact information.

Has Michael L. Levitz been buying or selling shares of Anika Therapeutics?

Michael L. Levitz has not been actively trading shares of Anika Therapeutics during the last quarter. Most recently, on Friday, March 11th, Michael L. Levitz bought 4,000 shares of Anika Therapeutics stock. The stock was acquired at an average cost of $24.62 per share, with a total value of $98,480.00. Learn More on Michael L. Levitz's trading history.

Who are Anika Therapeutics' active insiders?

Anika Therapeutics' insider roster includes John Hennemann, III (Director), Raymond Land (Director), and Michael Levitz (CFO). Learn More on Anika Therapeutics' active insiders.

Michael L. Levitz Insider Trading History at Anika Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2022Buy4,000$24.62$98,480.00View SEC Filing Icon  
8/11/2021Buy2,850$40.21$114,598.50View SEC Filing Icon  
See Full Table

Michael L. Levitz Buying and Selling Activity at Anika Therapeutics

This chart shows Michael L Levitz's buying and selling at Anika Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anika Therapeutics Company Overview

Anika Therapeutics logo
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $25.40
Low: $25.24
High: $25.62

50 Day Range

MA: $24.55
Low: $22.24
High: $26.42

2 Week Range

Now: $25.40
Low: $16.54
High: $29.25

Volume

83,692 shs

Average Volume

85,816 shs

Market Capitalization

$377.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75